Metabolic profiling identifies lung tumor responsiveness to erlotinib

Teresa W.M. Fan; Andrew N. Lane; Richard M. Higashi; Michael Bousamra; Goetz Kloecker; Donald M. Miller

doi:10.1016/j.yexmp.2009.04.004

Metabolic profiling identifies lung tumor responsiveness to erlotinib

Teresa W.M. Fan, Andrew N. Lane, Richard M. Higashi, Michael Bousamra, Goetz Kloecker, Donald M. Miller

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.

Original language	English
Pages (from-to)	83-86
Number of pages	4
Journal	Experimental and Molecular Pathology
Volume	87
Issue number	1
DOIs	https://doi.org/10.1016/j.yexmp.2009.04.004
State	Published - Aug 2009

Bibliographical note

Funding Information:
This study was supported by NIH Grant Number RR018733 from the National Center for Research Resources, National Science Foundation EPSCoR grant # EPS-0447479, NCI 1R01CA118434-01, the KY Lung Cancer Research Program, Kentucky Challenge for Excellence, and the Brown Foundation. We thank Ms. Lynn Deleeuw and Ms. Vennila Arumugum for sample processing.

Keywords

Bronchioalveolar adenocarcinoma
Erlotinib
Metabolomics

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Biology
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.yexmp.2009.04.004

Cite this

@article{ec7ba5cb1b2b44829f05aa2117163350,

title = "Metabolic profiling identifies lung tumor responsiveness to erlotinib",

abstract = "A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.",

keywords = "Bronchioalveolar adenocarcinoma, Erlotinib, Metabolomics",

author = "Fan, {Teresa W.M.} and Lane, {Andrew N.} and Higashi, {Richard M.} and Michael Bousamra and Goetz Kloecker and Miller, {Donald M.}",

note = "Funding Information: This study was supported by NIH Grant Number RR018733 from the National Center for Research Resources, National Science Foundation EPSCoR grant # EPS-0447479, NCI 1R01CA118434-01, the KY Lung Cancer Research Program, Kentucky Challenge for Excellence, and the Brown Foundation. We thank Ms. Lynn Deleeuw and Ms. Vennila Arumugum for sample processing.",

year = "2009",

month = aug,

doi = "10.1016/j.yexmp.2009.04.004",

language = "English",

volume = "87",

pages = "83--86",

number = "1",

}

TY - JOUR

T1 - Metabolic profiling identifies lung tumor responsiveness to erlotinib

AU - Fan, Teresa W.M.

AU - Lane, Andrew N.

AU - Higashi, Richard M.

AU - Bousamra, Michael

AU - Kloecker, Goetz

AU - Miller, Donald M.

N1 - Funding Information: This study was supported by NIH Grant Number RR018733 from the National Center for Research Resources, National Science Foundation EPSCoR grant # EPS-0447479, NCI 1R01CA118434-01, the KY Lung Cancer Research Program, Kentucky Challenge for Excellence, and the Brown Foundation. We thank Ms. Lynn Deleeuw and Ms. Vennila Arumugum for sample processing.

PY - 2009/8

Y1 - 2009/8

N2 - A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.

AB - A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.

KW - Bronchioalveolar adenocarcinoma

KW - Erlotinib

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=67649446283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649446283&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2009.04.004

DO - 10.1016/j.yexmp.2009.04.004

M3 - Article

C2 - 19409891

AN - SCOPUS:67649446283

SN - 0014-4800

VL - 87

SP - 83

EP - 86

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

IS - 1

ER -

Metabolic profiling identifies lung tumor responsiveness to erlotinib

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this